Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 962,834
  • Shares Outstanding, K 48,628
  • Annual Sales, $ 1,520 K
  • Annual Income, $ -73,160 K
  • 60-Month Beta 1.59
  • Price/Sales 618.99
  • Price/Cash Flow N/A
  • Price/Book 4.01
Trade SNDX with:

Options Overview

Details
  • Implied Volatility 65.26%
  • Historical Volatility 32.10%
  • IV Percentile 2%
  • IV Rank 8.82%
  • IV High 221.12% on 12/01/20
  • IV Low 50.18% on 06/23/21
  • Put/Call Vol Ratio 0.04
  • Today's Volume 629
  • Volume Avg (30-Day) 89
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 727
  • Open Int (30-Day) 272

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.62
  • Number of Estimates 3
  • High Estimate -0.58
  • Low Estimate -0.65
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -34.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.26 +29.75%
on 08/20/21
20.32 -2.56%
on 09/17/21
+3.81 (+23.83%)
since 08/17/21
3-Month
13.58 +45.80%
on 08/05/21
20.32 -2.56%
on 09/17/21
+0.23 (+1.18%)
since 06/17/21
52-Week
13.02 +52.07%
on 04/21/21
27.85 -28.90%
on 12/07/20
+2.74 (+16.06%)
since 09/17/20

Most Recent Stories

More News
Syndax Appoints Martin H. Huber, M.D., to its Board of Directors

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced...

SNDX : 19.80 (+2.54%)
Syndax Announces Participation at Three Upcoming Investor Conferences

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced...

SNDX : 19.80 (+2.54%)
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Misses Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of 40.54% and -24.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 19.80 (+2.54%)
Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported...

SNDX : 19.80 (+2.54%)
Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced...

SNDX : 19.80 (+2.54%)
SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced...

SNDX : 19.80 (+2.54%)
Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 19.80 (+2.54%)
Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 19.80 (+2.54%)
Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 19.80 (+2.54%)
Syndax Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 11, 2021 / Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 11, 2021 at 4:30...

SNDX : 19.80 (+2.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 21.21
2nd Resistance Point 20.77
1st Resistance Point 20.28
Last Price 19.80
1st Support Level 19.35
2nd Support Level 18.91
3rd Support Level 18.42

See More

52-Week High 27.85
Fibonacci 61.8% 22.18
Fibonacci 50% 20.44
Last Price 19.80
Fibonacci 38.2% 18.69
52-Week Low 13.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar